Skip to main content
Top

25-04-2024 | Ketamine

Psychotherapeutic Interventions in Clinical Trials of Psychedelics for the Treatment of Alcohol Use Disorder

Authors: Ardavan Mohammad Aghaei, Jeremy Weleff, Bradford Martins, Kevin Ing, Rodrigo Fontenele, Brian S. Barnett, Akhil Anand, Anahita Bassir Nia

Published in: Current Addiction Reports

Login to get access

Abstract

Purpose of Review

Alcohol use disorder (AUD) is the most common substance use disorder in the USA, with a considerable burden of disease. In recent years, psychedelics have emerged as particularly promising in treating AUD. In this paper, we review trials of classic and non-classic psychedelics in the treatment of AUD to determine whether there is substantial evidence, either confirming or refuting the need for accompanying psychotherapy on clinical effect for the treatment of AUD and whether any of the therapy methods are superior to others in this context.

Recent Findings

We found no study directly comparing different modalities of psychotherapy. Most trials did not include a psychotherapy-free arm to assess the psychedelic compounds independently. Only a few studies have compared arms with and without psychotherapy and no significant differences in the magnitude of improvement between arms were found. Moreover, many of the trials with a psychotherapy-free arm had methodological shortcomings such as poorly defined outcomes, small numbers of participants, and short follow-up periods.

Summary

There is a lack of high-quality empirical evidence confirming or refuting the necessity for concomitantly delivered psychotherapy during psychedelic trials for AUD. Therefore, future clinical trials should be designed in a manner that can shed light on the relationship between psychedelic treatment and use of psychotherapy.
Appendix
Available only for authorised users
Literature
3.
go back to reference Esser MB, Sherk A, Liu Y, Naimi TS, Stockwell T, Stahre M, et al. Deaths and years of potential life lost from excessive alcohol use—United States, 2011–2015. Morb Mortal Wkly Rep. 2020;69(39):1428.CrossRef Esser MB, Sherk A, Liu Y, Naimi TS, Stockwell T, Stahre M, et al. Deaths and years of potential life lost from excessive alcohol use—United States, 2011–2015. Morb Mortal Wkly Rep. 2020;69(39):1428.CrossRef
6.
go back to reference Ray LA, Bujarski S, Grodin E, Hartwell E, Green R, Venegas A, et al. State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. Am J Drug Alcohol Abuse. 2019;45(2):124–40.PubMedCrossRef Ray LA, Bujarski S, Grodin E, Hartwell E, Green R, Venegas A, et al. State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. Am J Drug Alcohol Abuse. 2019;45(2):124–40.PubMedCrossRef
10.
go back to reference Calleja-Conde J, Morales-García JA, Echeverry-Alzate V, Bühler KM, Giné E, López-Moreno JA. Classic psychedelics and alcohol use disorders: a systematic review of human and animal studies. Addict Biol. 2022;27(6): e13229.PubMedCrossRef Calleja-Conde J, Morales-García JA, Echeverry-Alzate V, Bühler KM, Giné E, López-Moreno JA. Classic psychedelics and alcohol use disorders: a systematic review of human and animal studies. Addict Biol. 2022;27(6): e13229.PubMedCrossRef
11.
go back to reference Zafar R, Siegel M, Harding R, Barba T, Agnorelli C, Suseelan S, et al. Psychedelic therapy in the treatment of addiction: the past, present and future. Front Psych. 2023;14:1183740.CrossRef Zafar R, Siegel M, Harding R, Barba T, Agnorelli C, Suseelan S, et al. Psychedelic therapy in the treatment of addiction: the past, present and future. Front Psych. 2023;14:1183740.CrossRef
12.
go back to reference Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiat. 2022;79(10):953–62.CrossRef Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiat. 2022;79(10):953–62.CrossRef
13.
go back to reference Bogenschutz MP, Forcehimes AA. Development of a psychotherapeutic model for psilocybin-assisted treatment of alcoholism. J Humanist Psychol. 2017;57(4):389–414.CrossRef Bogenschutz MP, Forcehimes AA. Development of a psychotherapeutic model for psilocybin-assisted treatment of alcoholism. J Humanist Psychol. 2017;57(4):389–414.CrossRef
14.
go back to reference Andersen KAA, Carhart-Harris R, Nutt DJ, Erritzoe D. Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies. Acta Psychiatr Scand. 2021;143(2):101–18.PubMedCrossRef Andersen KAA, Carhart-Harris R, Nutt DJ, Erritzoe D. Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies. Acta Psychiatr Scand. 2021;143(2):101–18.PubMedCrossRef
15.
go back to reference Fond G, Loundou A, Rabu C, Macgregor A, Lançon C, Brittner M, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology. 2014;231:3663–76.PubMedCrossRef Fond G, Loundou A, Rabu C, Macgregor A, Lançon C, Brittner M, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology. 2014;231:3663–76.PubMedCrossRef
17.
go back to reference Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 2018;235:399–408.PubMedCrossRef Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 2018;235:399–408.PubMedCrossRef
18.
go back to reference Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiat. 2021;78(5):481–9.CrossRef Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiat. 2021;78(5):481–9.CrossRef
19.
go back to reference Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165–80.PubMedPubMedCentralCrossRef Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165–80.PubMedPubMedCentralCrossRef
20.
go back to reference Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402–11.PubMedCrossRef Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402–11.PubMedCrossRef
23.
go back to reference Olson DE. The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacology & Translational Science. 2020;4(2):563–7.CrossRef Olson DE. The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacology & Translational Science. 2020;4(2):563–7.CrossRef
24.
go back to reference Pahnke WN, Kurland AA, Unger S, Savage C, Grof S. The experimental use of psychedelic (LSD) psychotherapy. JAMA. 1970;212(11):1856–63.PubMedCrossRef Pahnke WN, Kurland AA, Unger S, Savage C, Grof S. The experimental use of psychedelic (LSD) psychotherapy. JAMA. 1970;212(11):1856–63.PubMedCrossRef
25.
go back to reference Passie T, Guss J, Krähenmann R. Lower-dose psycholytic therapy—a neglected approach. Front Psych. 2022;13:1020505.CrossRef Passie T, Guss J, Krähenmann R. Lower-dose psycholytic therapy—a neglected approach. Front Psych. 2022;13:1020505.CrossRef
27.
go back to reference Richards WA. Psychedelic psychotherapy: insights from 25 years of research. J Humanist Psychol. 2017;57(4):323–37.CrossRef Richards WA. Psychedelic psychotherapy: insights from 25 years of research. J Humanist Psychol. 2017;57(4):323–37.CrossRef
28.
go back to reference Garcia-Romeu A, Richards WA. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. Int Rev Psychiatry. 2018;30(4):291–316.PubMedCrossRef Garcia-Romeu A, Richards WA. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. Int Rev Psychiatry. 2018;30(4):291–316.PubMedCrossRef
29.
go back to reference Nielson EM, May DG, Forcehimes AA, Bogenschutz MP. The psychedelic debriefing in alcohol dependence treatment: illustrating key change phenomena through qualitative content analysis of clinical sessions. Front Pharmacol. 2018;9:132.PubMedPubMedCentralCrossRef Nielson EM, May DG, Forcehimes AA, Bogenschutz MP. The psychedelic debriefing in alcohol dependence treatment: illustrating key change phenomena through qualitative content analysis of clinical sessions. Front Pharmacol. 2018;9:132.PubMedPubMedCentralCrossRef
30.
go back to reference Bennett R, Yavorsky C, Bravo G. Ketamine for bipolar depression: biochemical, psychotherapeutic, and psychedelic approaches. Front Psych. 2022;13: 867484.CrossRef Bennett R, Yavorsky C, Bravo G. Ketamine for bipolar depression: biochemical, psychotherapeutic, and psychedelic approaches. Front Psych. 2022;13: 867484.CrossRef
31.
go back to reference Krediet E, Bostoen T, Breeksema J, van Schagen A, Passie T, Vermetten E. Reviewing the potential of psychedelics for the treatment of PTSD. Int J Neuropsychopharmacol. 2020;23(6):385–400.PubMedPubMedCentralCrossRef Krediet E, Bostoen T, Breeksema J, van Schagen A, Passie T, Vermetten E. Reviewing the potential of psychedelics for the treatment of PTSD. Int J Neuropsychopharmacol. 2020;23(6):385–400.PubMedPubMedCentralCrossRef
32.
go back to reference Hollister LE, Shelton J, Krieger G. A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetamine in alcoholics. Am J Psychiatry. 1969;125(10):1352–7.PubMedCrossRef Hollister LE, Shelton J, Krieger G. A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetamine in alcoholics. Am J Psychiatry. 1969;125(10):1352–7.PubMedCrossRef
33.
go back to reference Smith CM. A new adjunct to the treatment of alcoholism: the hallucinogenic drugs. Q J Stud Alcohol. 1958;19(3):406–17.PubMedCrossRef Smith CM. A new adjunct to the treatment of alcoholism: the hallucinogenic drugs. Q J Stud Alcohol. 1958;19(3):406–17.PubMedCrossRef
34.
go back to reference Chwelos N, Blewett DB, Smith CM, Hoffer A. Use of d-lysergic acid diethylamide in the treatment of alcoholism. Q J Stud Alcohol. 1959;20(3):577–90.PubMedCrossRef Chwelos N, Blewett DB, Smith CM, Hoffer A. Use of d-lysergic acid diethylamide in the treatment of alcoholism. Q J Stud Alcohol. 1959;20(3):577–90.PubMedCrossRef
35.
go back to reference Rolo A, Krinsky LW, Goldfarb L. LSD as an adjunct to psychotherapy with alcoholics. J Psychol. 1960;50(1):85–104.CrossRef Rolo A, Krinsky LW, Goldfarb L. LSD as an adjunct to psychotherapy with alcoholics. J Psychol. 1960;50(1):85–104.CrossRef
36.
go back to reference MacLean JR, MacDonald DC, Byrne UP, Hubbard AM. The use of LSD-25 in the treatment of alcoholism and other psychiatric problems. Q J Stud Alcohol. 1961;22(1):34–45.PubMedCrossRef MacLean JR, MacDonald DC, Byrne UP, Hubbard AM. The use of LSD-25 in the treatment of alcoholism and other psychiatric problems. Q J Stud Alcohol. 1961;22(1):34–45.PubMedCrossRef
37.
go back to reference Jensen SE. A treatment program for alcoholics in a mental hospital. Q J Stud Alcohol. 1962;23(2):315–20.PubMedCrossRef Jensen SE. A treatment program for alcoholics in a mental hospital. Q J Stud Alcohol. 1962;23(2):315–20.PubMedCrossRef
38.
go back to reference Jensen SE, Ramsay R. Treatment of chronic alcoholism with lysergic acid diethylamide. Can Psychiatr Assoc J. 1963;8(3):182–8.PubMedCrossRef Jensen SE, Ramsay R. Treatment of chronic alcoholism with lysergic acid diethylamide. Can Psychiatr Assoc J. 1963;8(3):182–8.PubMedCrossRef
39.
40.
go back to reference Smart RG, Storm T, Baker EFW, Solursh L. A controlled study of lysergide in the treatment of alcoholism. I. The effects on drinking behavior. Q J Stud Alcohol. 1966;27(3):469–82.PubMedCrossRef Smart RG, Storm T, Baker EFW, Solursh L. A controlled study of lysergide in the treatment of alcoholism. I. The effects on drinking behavior. Q J Stud Alcohol. 1966;27(3):469–82.PubMedCrossRef
41.
go back to reference Van Dusen W, Wilson W, Miners W, Hook H. Treatment of alcoholism with lysergide. Q J Stud Alcohol. 1967;28(2):295–304.PubMedCrossRef Van Dusen W, Wilson W, Miners W, Hook H. Treatment of alcoholism with lysergide. Q J Stud Alcohol. 1967;28(2):295–304.PubMedCrossRef
43.
go back to reference Ludwig A, Levine J, Stark L, Lazar R. A clinical study of LSD treatment in alcoholism. Am J Psychiatry. 1969;126(1):59–69.PubMedCrossRef Ludwig A, Levine J, Stark L, Lazar R. A clinical study of LSD treatment in alcoholism. Am J Psychiatry. 1969;126(1):59–69.PubMedCrossRef
44.
go back to reference Bowen WT, Soskin RA, Chotlos JW. Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: a follow-up study. J Nerv Ment Dis. 1970;150(2):111–8.PubMedCrossRef Bowen WT, Soskin RA, Chotlos JW. Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: a follow-up study. J Nerv Ment Dis. 1970;150(2):111–8.PubMedCrossRef
45.
go back to reference Tomsovic M, Edwards RV. Lysergide treatment of schizophrenic and nonschizophrenic alcoholics; a controlled evaluation. Q J Stud Alcohol. 1970;31(4):932–49.PubMedCrossRef Tomsovic M, Edwards RV. Lysergide treatment of schizophrenic and nonschizophrenic alcoholics; a controlled evaluation. Q J Stud Alcohol. 1970;31(4):932–49.PubMedCrossRef
46.
go back to reference Kurland A, Savage C, Pahnke WN, Grof S, Olsson JE. LSD in the treatment of alcoholics. Pharmacopsychiatry. 1971;4(02):83–94.CrossRef Kurland A, Savage C, Pahnke WN, Grof S, Olsson JE. LSD in the treatment of alcoholics. Pharmacopsychiatry. 1971;4(02):83–94.CrossRef
47.
go back to reference Faillace LA, Vourlekis A, Szara S. Hallucinogenic drugs in the treatment of alcoholism: a two-year follow-up. Compr Psychiatry. 1970;11(1):51–6.PubMedCrossRef Faillace LA, Vourlekis A, Szara S. Hallucinogenic drugs in the treatment of alcoholism: a two-year follow-up. Compr Psychiatry. 1970;11(1):51–6.PubMedCrossRef
48.
go back to reference Grof S, Soskin RA, Richards WA, Kurland AA. DPT as an adjunct in psychotherapy of alcoholics. Int Pharmacopsychiatry. 1973;8(1–2):104–15.PubMedCrossRef Grof S, Soskin RA, Richards WA, Kurland AA. DPT as an adjunct in psychotherapy of alcoholics. Int Pharmacopsychiatry. 1973;8(1–2):104–15.PubMedCrossRef
49.
go back to reference Rhead JC, Soskin RA, Turek I, Richards WA, Yensen R, Kurland AA, et al. Psychedelic drug (DPT)-assisted psychotherapy with alcoholics: a controlled study. J Psychedelic Drugs. 1977;9(4):287–300.CrossRef Rhead JC, Soskin RA, Turek I, Richards WA, Yensen R, Kurland AA, et al. Psychedelic drug (DPT)-assisted psychotherapy with alcoholics: a controlled study. J Psychedelic Drugs. 1977;9(4):287–300.CrossRef
50.
go back to reference Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Bigelow R, Barbosa PCR. A pilot study of psilocybin-assisted treatment for alcohol dependence: acute effects and short-term alcohol use, self-efficacy, and craving. Alcohol: Clin Exp Res. 2014;38:155A-A. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Bigelow R, Barbosa PCR. A pilot study of psilocybin-assisted treatment for alcohol dependence: acute effects and short-term alcohol use, self-efficacy, and craving. Alcohol: Clin Exp Res. 2014;38:155A-A.
51.
go back to reference Bogenschutz M. Mood, craving, and self-efficacy in psilocybin-assisted treatment of alcoholism. Neuropsychopharmacology. 2015;40:S90-S. Bogenschutz M. Mood, craving, and self-efficacy in psilocybin-assisted treatment of alcoholism. Neuropsychopharmacology. 2015;40:S90-S.
52.
go back to reference Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29(3):289–99.PubMedCrossRef Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29(3):289–99.PubMedCrossRef
53.
go back to reference Sessa B, Sakal C, O’Brien S, Nutt D. First study of safety and tolerability of 3, 4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants. BMJ Case Rep CP. 2019;12(7): e230109.CrossRef Sessa B, Sakal C, O’Brien S, Nutt D. First study of safety and tolerability of 3, 4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants. BMJ Case Rep CP. 2019;12(7): e230109.CrossRef
54.
go back to reference Sessa B, Higbed L, O’Brien S, Durant C, Sakal C, Titheradge D, et al. First study of safety and tolerability of 3, 4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. J Psychopharmacol. 2021;35(4):375–83.PubMedCrossRef Sessa B, Higbed L, O’Brien S, Durant C, Sakal C, Titheradge D, et al. First study of safety and tolerability of 3, 4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. J Psychopharmacol. 2021;35(4):375–83.PubMedCrossRef
55.
go back to reference Nicholas CR, Wang JB, Coker A, Mitchell JM, Klaire SS, Yazar-Klosinski B, et al. The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. Drug Alcohol Depend. 2022;233: 109356.PubMedPubMedCentralCrossRef Nicholas CR, Wang JB, Coker A, Mitchell JM, Klaire SS, Yazar-Klosinski B, et al. The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. Drug Alcohol Depend. 2022;233: 109356.PubMedPubMedCentralCrossRef
56.
go back to reference Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025–33.PubMedPubMedCentralCrossRef Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025–33.PubMedPubMedCentralCrossRef
57.
go back to reference Krupitsky EM, Grineko AY, Berkaliev TN, Paley AI, Tetrov UN, Mushkov KA, et al. The combination of psychedelic and aversive approaches in alcoholism treatment: the affective contra-attribution method. Alcohol Treat Q. 1992;9(1):99–105.CrossRef Krupitsky EM, Grineko AY, Berkaliev TN, Paley AI, Tetrov UN, Mushkov KA, et al. The combination of psychedelic and aversive approaches in alcoholism treatment: the affective contra-attribution method. Alcohol Treat Q. 1992;9(1):99–105.CrossRef
58.
go back to reference Krystal JH, Petrakis IL, Webb E, Cooney NL, Karper LP, Namanworth S, et al. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry. 1998;55(4):354–60.PubMedCrossRef Krystal JH, Petrakis IL, Webb E, Cooney NL, Karper LP, Namanworth S, et al. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry. 1998;55(4):354–60.PubMedCrossRef
60.
go back to reference Yoon G, Niciu MJ, Ralevski E, Arias AJ, Limoncelli D, Newcomb J, et al. A single infusion of the NMDA receptor antagonist ketamine in comorbid depression and alcohol use disorder. Alcohol: Clin Exp Res. 2016;40:96A-A. Yoon G, Niciu MJ, Ralevski E, Arias AJ, Limoncelli D, Newcomb J, et al. A single infusion of the NMDA receptor antagonist ketamine in comorbid depression and alcohol use disorder. Alcohol: Clin Exp Res. 2016;40:96A-A.
61.
go back to reference Yoon G, Ralevski E, Abdallah CG, Arias AJ, Limoncelli D, Newcomb J, et al. Repeated ketamine treatment for comorbid major depressive disorder and alcohol use disorder. Alcohol: Clin Exp Res. 2016;40:97A-A. Yoon G, Ralevski E, Abdallah CG, Arias AJ, Limoncelli D, Newcomb J, et al. Repeated ketamine treatment for comorbid major depressive disorder and alcohol use disorder. Alcohol: Clin Exp Res. 2016;40:97A-A.
62.
go back to reference Yoon G, Ralevski E, Arias AJ, Limoncelli D, Newcomb J, Levy L, et al. Naltrexone plus ketamine for the treatment of major depressive disorder and alcohol use disorder. Alcohol: Clin Exp Res. 2018;42:236A-A. Yoon G, Ralevski E, Arias AJ, Limoncelli D, Newcomb J, Levy L, et al. Naltrexone plus ketamine for the treatment of major depressive disorder and alcohol use disorder. Alcohol: Clin Exp Res. 2018;42:236A-A.
63.
go back to reference Yoon G, Petrakis IL, Krystal JH. Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder. JAMA Psychiat. 2019;76(3):337–8.CrossRef Yoon G, Petrakis IL, Krystal JH. Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder. JAMA Psychiat. 2019;76(3):337–8.CrossRef
64.
go back to reference Dakwar E, Levin F, Hart CL, Basaraba C, Choi J, Pavlicova M, et al. A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. Am J Psychiatry. 2020;177(2):125–33.PubMedCrossRef Dakwar E, Levin F, Hart CL, Basaraba C, Choi J, Pavlicova M, et al. A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. Am J Psychiatry. 2020;177(2):125–33.PubMedCrossRef
65.
go back to reference Rothberg RL, Azhari N, Haug NA, Dakwar E. Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: results from a randomized, controlled trial. J Psychopharmacol. 2021;35(2):150–8.PubMedCrossRef Rothberg RL, Azhari N, Haug NA, Dakwar E. Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: results from a randomized, controlled trial. J Psychopharmacol. 2021;35(2):150–8.PubMedCrossRef
66.
go back to reference Das RK, Gale G, Walsh K, Hennessy VE, Iskandar G, Mordecai LA, et al. Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories. Nat Commun. 2019;10(1):5187.PubMedPubMedCentralCrossRef Das RK, Gale G, Walsh K, Hennessy VE, Iskandar G, Mordecai LA, et al. Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories. Nat Commun. 2019;10(1):5187.PubMedPubMedCentralCrossRef
67.
go back to reference Mollaahmetoglu OM, Keeler J, Ashbullby KJ, Ketzitzidou-Argyri E, Grabski M, Morgan CJA. “This is something that changed my life”: a qualitative study of patients' experiences in a clinical trial of ketamine treatment for alcohol use disorders. Front Psychiatry. 2021;12:695335. https://doi.org/10.3389/fpsyt.2021.695335. Mollaahmetoglu OM, Keeler J, Ashbullby KJ, Ketzitzidou-Argyri E, Grabski M, Morgan CJA. “This is something that changed my life”: a qualitative study of patients' experiences in a clinical trial of ketamine treatment for alcohol use disorders. Front Psychiatry. 2021;12:695335. https://​doi.​org/​10.​3389/​fpsyt.​2021.​695335.
68.
go back to reference Grabski M, McAndrew A, Lawn W, Marsh B, Raymen L, Stevens T, et al. Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder. Am J Psychiatry. 2022;179(2):152–62.PubMedCrossRef Grabski M, McAndrew A, Lawn W, Marsh B, Raymen L, Stevens T, et al. Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder. Am J Psychiatry. 2022;179(2):152–62.PubMedCrossRef
70.
go back to reference Yaden DB, Griffiths RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2020;4(2):568–72.PubMedPubMedCentralCrossRef Yaden DB, Griffiths RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2020;4(2):568–72.PubMedPubMedCentralCrossRef
71.
go back to reference Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181–97.PubMedPubMedCentralCrossRef Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181–97.PubMedPubMedCentralCrossRef
72.
go back to reference Feduccia A, Agin-Liebes G, Price CM, Grinsell N, Paradise S, Rabin DM. The need for establishing best practices and gold standards in psychedelic medicine. J Affect Disord. 2023;332:47–54.PubMedCrossRef Feduccia A, Agin-Liebes G, Price CM, Grinsell N, Paradise S, Rabin DM. The need for establishing best practices and gold standards in psychedelic medicine. J Affect Disord. 2023;332:47–54.PubMedCrossRef
73.
go back to reference Heifets BD, Malenka RC. Disruptive psychopharmacology. JAMA Psychiat. 2019;76(8):775–6.CrossRef Heifets BD, Malenka RC. Disruptive psychopharmacology. JAMA Psychiat. 2019;76(8):775–6.CrossRef
75.
go back to reference Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, et al. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature. 2021;589(7842):474–9.PubMedCrossRef Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, et al. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature. 2021;589(7842):474–9.PubMedCrossRef
76.
go back to reference Yaden DB, Earp D, Graziosi M, Friedman-Wheeler D, Luoma JB, Johnson MW. Psychedelics and psychotherapy: cognitive-behavioral approaches as default. Front Psychol. 2022;13:1604.CrossRef Yaden DB, Earp D, Graziosi M, Friedman-Wheeler D, Luoma JB, Johnson MW. Psychedelics and psychotherapy: cognitive-behavioral approaches as default. Front Psychol. 2022;13:1604.CrossRef
77.
go back to reference Harris JC. Psychedelic-assisted psychotherapy and Carl Jung’s Red Book. JAMA Psychiat. 2021;78(8):815–6.CrossRef Harris JC. Psychedelic-assisted psychotherapy and Carl Jung’s Red Book. JAMA Psychiat. 2021;78(8):815–6.CrossRef
78.
80.
go back to reference Glowacki DR, Wonnacott MD, Freire R, Glowacki BR, Gale EM, Pike JE, et al. Isness: using multi-person VR to design peak mystical type experiences comparable to psychedelics. Proceedings of the 2020 CHI Conference on Human Factors in Computing Systems; 2020. pp. 1–14. https://doi.org/10.1145/3313831.3376649. Glowacki DR, Wonnacott MD, Freire R, Glowacki BR, Gale EM, Pike JE, et al. Isness: using multi-person VR to design peak mystical type experiences comparable to psychedelics. Proceedings of the 2020 CHI Conference on Human Factors in Computing Systems; 2020. pp. 1–14. https://​doi.​org/​10.​1145/​3313831.​3376649.
Metadata
Title
Psychotherapeutic Interventions in Clinical Trials of Psychedelics for the Treatment of Alcohol Use Disorder
Authors
Ardavan Mohammad Aghaei
Jeremy Weleff
Bradford Martins
Kevin Ing
Rodrigo Fontenele
Brian S. Barnett
Akhil Anand
Anahita Bassir Nia
Publication date
25-04-2024
Publisher
Springer International Publishing
Published in
Current Addiction Reports
Electronic ISSN: 2196-2952
DOI
https://doi.org/10.1007/s40429-024-00574-y